

# Ali Rihani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5351542/publications.pdf>

Version: 2024-02-01

19  
papers

961  
citations

623734

14  
h-index

794594

19  
g-index

19  
all docs

19  
docs citations

19  
times ranked

2312  
citing authors

#	ARTICLE	IF	CITATIONS
1	A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. <i>Cancers</i> , 2021, 13, 1807.	3.7	4
2	Identification and targeting of selective vulnerability rendered by tamoxifen resistance. <i>Breast Cancer Research</i> , 2020, 22, 80.	5.0	11
3	Thermal Proteome Profiling Identifies Oxidative-Dependent Inhibition of the Transcription of Major Oncogenes as a New Therapeutic Mechanism for Select Anticancer Compounds. <i>Cancer Research</i> , 2020, 80, 1538-1550.	0.9	19
4	Cost-effective and robust genotyping using double-mismatch allele-specific quantitative PCR. <i>Scientific Reports</i> , 2019, 9, 2150.	3.3	27
5	Expressed repetitive elements are broadly applicable reference targets for normalization of reverse transcription-qPCR data in mice. <i>Scientific Reports</i> , 2018, 8, 7642.	3.3	10
6	Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma. <i>Cancer Cell International</i> , 2015, 15, 76.	4.1	38
7	Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma. <i>Scientific Reports</i> , 2015, 5, 9027.	3.3	29
8	Expressed Repeat Elements Improve RT-qPCR Normalization across a Wide Range of Zebrafish Gene Expression Studies. <i>PLoS ONE</i> , 2014, 9, e109091.	2.5	38
9	CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients. <i>PLoS ONE</i> , 2014, 9, e114696.	2.5	15
10	miRBase Tracker: keeping track of microRNA annotation changes. <i>Database: the Journal of Biological Databases and Curation</i> , 2014, 2014, .	3.0	73
11	Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1867-1870.	1.5	5
12	Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer. <i>Cancer Letters</i> , 2014, 344, 157-165.	7.2	39
13	The need for transparency and good practices in the qPCR literature. <i>Nature Methods</i> , 2013, 10, 1063-1067.	19.0	251
14	Effective Alu Repeat Based RT-Qpcr Normalization in Cancer Cell Perturbation Experiments. <i>PLoS ONE</i> , 2013, 8, e71776.	2.5	13
15	17q24.2 microdeletions: a new syndromal entity with intellectual disability, truncal obesity, mood swings and hallucinations. <i>European Journal of Human Genetics</i> , 2012, 20, 534-539.	2.8	28
16	Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 983-993.	4.1	61
17	An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. <i>Oncogene</i> , 2010, 29, 3583-3592.	5.9	141
18	Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1562-1574.	6.3	105

#	ARTICLE	IF	CITATIONS
19	Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14ARF-MDM2-p53 axis. <i>Cell Death and Differentiation</i> , 2009, 16, 1563-1572.	11.2	54